Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals Ltd. has announced a change in the director’s interest, specifically involving Harry Kevin McCann, who has disposed of 30,000 fully paid ordinary shares at $30.43 per share. This transaction reflects a minor adjustment in the director’s holdings, with implications for the company’s governance and shareholder structure, although it does not significantly impact the company’s overall market position or operations.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets oncology markets, aiming to provide innovative solutions for cancer diagnosis and treatment.
YTD Price Performance: 26.44%
Average Trading Volume: 4,579
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.97B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.